

FZD9 Antibody (C-Term)
Peptide-affinity purified goat antibody
Catalog # AF2751a**Specification**

FZD9 Antibody (C-Term) - Product Information

| | |
|-------------------|--|
| Application | IHC, E |
| Primary Accession | O00144 |
| Other Accession | NP_003499.1 , 8326 |
| Reactivity | Human |
| Predicted | Mouse, Rat |
| Host | Goat |
| Clonality | Polyclonal |
| Concentration | 0.5 mg/ml |
| Isotype | IgG |
| Calculated MW | 64466 |

FZD9 Antibody (C-Term) - Additional Information**Gene ID** 8326**Other Names**

Frizzled-9, Fz-9, hFz9, FzE6, CD349, FZD9, FZD3

Dilution

IHC~~1:100~500

E~~N/A

Format

0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

FZD9 Antibody (C-Term) is for research use only and not for use in diagnostic or therapeutic procedures.

FZD9 Antibody (C-Term) - Protein Information**Name** FZD9**Synonyms** FZD3**Function**

Receptor for WNT2 that is coupled to the beta-catenin canonical signaling pathway, which leads to

the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes (By similarity). Plays a role in neuromuscular junction (NMJ) assembly by negatively regulating the clustering of acetylcholine receptors (AChR) through the beta-catenin canonical signaling pathway (By similarity). May play a role in neural progenitor cells (NPCs) viability through the beta- catenin canonical signaling pathway by negatively regulating cell cycle arrest leading to inhibition of neuron apoptotic process (PubMed:27509850). During hippocampal development, regulates neuroblast proliferation and apoptotic cell death. Controls bone formation through non canonical Wnt signaling mediated via ISG15. Positively regulates bone regeneration through non canonical Wnt signaling (By similarity).

Cellular Location

Cell membrane {ECO:0000250|UniProtKB:Q9R216}; Multi-pass membrane protein.
Note=Relocalizes DVL1 to the cell membrane leading to phosphorylation of DVL1 and AXIN1 relocalization to the cell membrane. {ECO:0000250|UniProtKB:Q8K4C8}

Tissue Location


Expressed predominantly in adult and fetal brain, testis, eye, skeletal muscle and kidney. Moderately expressed in pancreas, thyroid, adrenal cortex, small intestine and stomach Detected in fetal liver and kidney. Expressed in neural progenitor cells (PubMed:27509850).

FZD9 Antibody (C-Term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

FZD9 Antibody (C-Term) - Images



AF2751a (5 µg/ml) staining of paraffin embedded Human Testis. Steamed antigen retrieval with citrate buffer pH 6, AP-staining.

FZD9 Antibody (C-Term) - References

Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma. Winn RA, Van

Scoyk M, Hammond M, Rodriguez K, Crossno JT Jr, Heasley LE, Nemenoff RA. J Biol Chem. 2006 Sep 15;281(37):26943-50. Epub 2006 Jul 11. PMID: 16835228